Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and Co ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.